AR104461A1 - Pirrolo[2,3-d]pirimidinil, pirrolo[2,3-b]pirazinil, pirrolo[2,3-b]piridinil acrilamidas y epóxidos de estas - Google Patents

Pirrolo[2,3-d]pirimidinil, pirrolo[2,3-b]pirazinil, pirrolo[2,3-b]piridinil acrilamidas y epóxidos de estas

Info

Publication number: AR104461A1
Authority: AR; Argentina
Prior art keywords: straight; branched chain; chain alkyl; aryl; heteroaryl
Prior art date: 2015-05-01

Application number

ARP160101237A

Other languages

English (en)

Spanish (es)

Inventor

Xi Liang Sidney

I TRUJILLO John

Jai Unwalla Rayomand

Telliez Jean

Merrill Baptiste - Hayward Matthew

Matthew Gilbert Adam

Edward Flanagan Mark

Che Ye

Casimiro-Garcia Agustin

Frank Brown Matthew

Thorarensen Atli

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-05-01

Filing date

2016-04-29

Publication date

2017-07-19

2016-04-29 Application filed by Pfizer filed Critical Pfizer

2017-07-19 Publication of AR104461A1 publication Critical patent/AR104461A1/es

Links

150000002118 epoxides Chemical class 0.000 title abstract 2
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 title 3
125000000217 alkyl group Chemical group 0.000 abstract 24
125000003118 aryl group Chemical group 0.000 abstract 6
-1 cyano, hydroxyl Chemical group 0.000 abstract 6
125000001072 heteroaryl group Chemical group 0.000 abstract 6
229910052739 hydrogen Inorganic materials 0.000 abstract 6
239000001257 hydrogen Substances 0.000 abstract 6
150000002431 hydrogen Chemical group 0.000 abstract 5
125000005010 perfluoroalkyl group Chemical group 0.000 abstract 5
125000000623 heterocyclic group Chemical group 0.000 abstract 4
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 3
125000000041 C6-C10 aryl group Chemical group 0.000 abstract 3
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 abstract 3
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 3
229910052805 deuterium Inorganic materials 0.000 abstract 3
229910052736 halogen Inorganic materials 0.000 abstract 3
150000002367 halogens Chemical class 0.000 abstract 3
125000003545 alkoxy group Chemical group 0.000 abstract 2
125000003282 alkyl amino group Chemical group 0.000 abstract 2
125000004429 atom Chemical group 0.000 abstract 2
125000004093 cyano group Chemical group *C#N 0.000 abstract 2
125000004663 dialkyl amino group Chemical group 0.000 abstract 2
125000005843 halogen group Chemical group 0.000 abstract 2
125000001424 substituent group Chemical group 0.000 abstract 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 abstract 1
239000005977 Ethylene Substances 0.000 abstract 1
229920001774 Perfluoroether Polymers 0.000 abstract 1
125000002877 alkyl aryl group Chemical group 0.000 abstract 1
125000006598 aminocarbonylamino group Chemical group 0.000 abstract 1
125000002619 bicyclic group Chemical group 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
125000002950 monocyclic group Chemical group 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Diabetes (AREA)
Hematology (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Psychology (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Transplantation (AREA)
Ophthalmology & Optometry (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Oncology (AREA)

ARP160101237A 2015-05-01 2016-04-29 Pirrolo[2,3-d]pirimidinil, pirrolo[2,3-b]pirazinil, pirrolo[2,3-b]piridinil acrilamidas y epóxidos de estas AR104461A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201562155824P	2015-05-01	2015-05-01

Publications (1)

Publication Number	Publication Date
AR104461A1 true AR104461A1 (es)	2017-07-19

Family

ID=55863136

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ARP160101237A AR104461A1 (es)	2015-05-01	2016-04-29	Pirrolo[2,3-d]pirimidinil, pirrolo[2,3-b]pirazinil, pirrolo[2,3-b]piridinil acrilamidas y epóxidos de estas

Country Status (8)

Country	Link
US (1)	US10703756B2 (2)
EP (1)	EP3288943B1 (2)
JP (1)	JP6761815B2 (2)
AR (1)	AR104461A1 (2)
CA (1)	CA2984183C (2)
ES (1)	ES2928757T3 (2)
TW (1)	TW201706274A (2)
WO (1)	WO2016178110A1 (2)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP7327802B2 (ja) *	2017-01-26	2023-08-16	アラクセスファーマエルエルシー	縮合ヘテロ－ヘテロ二環式化合物およびその使用方法
WO2018140599A1 (en)	2017-01-26	2018-08-02	Araxes Pharma Llc	Benzothiophene and benzothiazole compounds and methods of use thereof
US11957931B2 (en) *	2017-04-26	2024-04-16	Yale University	Compositions and methods for treating vitiligo
WO2018218069A1 (en)	2017-05-25	2018-11-29	Araxes Pharma Llc	Quinazoline derivatives as modulators of mutant kras, hras or nras
AU2018312349A1 (en)	2017-08-01	2020-02-06	Theravance Biopharma R&D Ip, Llc	Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors
BR112020018094A2 (pt)	2018-03-08	2020-12-22	Incyte Corporation	Compostos de aminopirazina diol como inibidores de pi3k-¿
US11046658B2 (en)	2018-07-02	2021-06-29	Incyte Corporation	Aminopyrazine derivatives as PI3K-γ inhibitors
MX2021000887A (es)	2018-08-01	2021-03-31	Araxes Pharma Llc	Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
CN119080779A (zh) *	2018-08-10	2024-12-06	阿克拉瑞斯治疗股份有限公司	吡咯并嘧啶itk抑制剂
CN113498352A (zh) *	2019-01-23	2021-10-12	施万生物制药研发Ip有限责任公司	作为jak抑制剂的咪唑并[1,5-a]吡啶、1,2,4-三唑并[4,3-a]吡啶和咪唑并[1,5-a]吡嗪
CN112430235B (zh) *	2019-08-26	2024-04-05	东莞市东阳光仿制药研发有限公司	一种pf-06651600中间体的制备方法
KR102228668B1 (ko) *	2019-10-08	2021-03-17	(주)부흥산업사	메틸피퍼리딘 아미노피롤로 피리미딘의 제조방법
CN111407767B (zh) *	2020-03-28	2021-05-25	中山大学	一种磺胺间甲氧嘧啶衍生物在制备抗肿瘤药物中的应用
WO2023151069A1 (zh) *	2022-02-14	2023-08-17	湖南南新制药股份有限公司	吡咯并[2,3-d]六元杂芳环衍生物、其制备方法和药物用途
CN119060058A (zh) *	2024-08-21	2024-12-03	武汉九州钰民医药科技有限公司	一种甲苯磺酸利特昔替尼的合成方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SK286640B6 (sk)	1998-06-19	2009-03-05	Pfizer Products Inc.	Pyrol [2,3-d] pyrimidínová zlúčenina, jej použitie na výrobu liečiva, farmaceutická kompozícia s jej obsahom, použitie jej kombinácie s ďalšími činidlami a súpravy s jej obsahom na výrobu liečiva
PA8474101A1 (es)	1998-06-19	2000-09-29	Pfizer Prod Inc	Compuestos de pirrolo [2,3-d] pirimidina
DE60037345T2 (de)	1999-12-10	2008-11-13	Pfizer Products Inc., Groton	Pyrrolo(2,3-d)pyrimidin-Verbindungen
ATE423120T1 (de)	2000-06-26	2009-03-15	Pfizer Prod Inc	Pyrroloä2,3-düpyrimidin verbindungen als immunosuppressive wirkstoffe
US7301023B2 (en)	2001-05-31	2007-11-27	Pfizer Inc.	Chiral salt resolution
AU2003278529A1 (en)	2002-11-21	2004-06-15	Pfizer Products Inc.	3-amino-piperidine derivatives and processes for their preparation
US7491827B2 (en)	2002-12-23	2009-02-17	Millennium Pharmaceuticals, Inc.	Aryl sulfonamides useful as inhibitors of chemokine receptor activity
NZ546055A (en)	2003-08-27	2010-05-28	Biota Scient Management	Novel tricyclic nucleosides or nucleotides as therapeutic agents
EP1913000B1 (en)	2005-07-29	2012-01-11	Pfizer Products Inc.	Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis
JP5098843B2 (ja)	2007-06-29	2012-12-12	Ｊｆｅスチール株式会社	金属試料中の着目元素の固溶含有率を求める方法
JP5368485B2 (ja)	2008-02-25	2013-12-18	エフ．ホフマン−ラロシュアーゲー	ピロロピラジンキナーゼインヒビター
JP5576370B2 (ja)	2008-08-06	2014-08-20	ファイザー・インク	Ｃｈｋ−１阻害剤としての６置換２−ヘテロシクリルアミノピラジン化合物
NZ598985A (en)	2009-09-04	2013-07-26	Biogen Idec Inc	Bruton's tyrosine kinase inhibitors
MX2012013378A (es)	2010-05-20	2013-01-24	Hoffmann La Roche	Derivados de pirrolo [2, 3-b] pirazina-7-carboxamida y sus uso como inhibidores de cinasa janus (jak) y cinasa tirosina del brazo (syk).
US9206188B2 (en) *	2013-04-18	2015-12-08	Arrien Pharmaceuticals Llc	Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
SI3077395T1 (en)	2013-12-05	2018-03-30	Pfizer Inc.	Pyrrolo(2,3-d)pyrimidinyl, pyrrolo(2,3-b)pyrazinyl and pyrrolo(2,3-d)pyridinyl acrylamides

2016
- 2016-04-19 EP EP16719917.3A patent/EP3288943B1/en active Active
- 2016-04-19 JP JP2017556831A patent/JP6761815B2/ja active Active
- 2016-04-19 US US15/569,874 patent/US10703756B2/en active Active
- 2016-04-19 ES ES16719917T patent/ES2928757T3/es active Active
- 2016-04-19 WO PCT/IB2016/052220 patent/WO2016178110A1/en not_active Ceased
- 2016-04-19 CA CA2984183A patent/CA2984183C/en active Active
- 2016-04-27 TW TW105113139A patent/TW201706274A/zh unknown
- 2016-04-29 AR ARP160101237A patent/AR104461A1/es unknown

Also Published As

Publication number	Publication date
US20190002466A1 (en)	2019-01-03
CA2984183C (en)	2021-11-09
JP2018514560A (ja)	2018-06-07
EP3288943B1 (en)	2022-09-28
JP6761815B2 (ja)	2020-09-30
EP3288943A1 (en)	2018-03-07
WO2016178110A1 (en)	2016-11-10
TW201706274A (zh)	2017-02-16
ES2928757T3 (es)	2022-11-22
US10703756B2 (en)	2020-07-07
CA2984183A1 (en)	2016-11-10

Legal Events

Date	Code	Title	Description
2018-01-30	FB	Suspension of granting procedure

Publication	Publication Date	Title
AR104461A1 (es)	2017-07-19	Pirrolo[2,3-d]pirimidinil, pirrolo[2,3-b]pirazinil, pirrolo[2,3-b]piridinil acrilamidas y epóxidos de estas
AR099363A1 (es)	2016-07-20	Pirrolo[2,3-d]pirimidinil, pirrolo[2,3-b]pirazinil y pirrolo[2,3-d]piridinil acrilamidas
AR123089A2 (es)	2022-10-26	Compuesto de piridinona
AR100438A1 (es)	2016-10-05	Pirazolopiridinas y pirazolopirimidinas
AR088760A1 (es)	2014-07-02	Derivados de pirrolopirimidina y purina
AR092742A1 (es)	2015-04-29	Piridinonas antifibroticas
AR096979A1 (es)	2016-02-10	Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CL2016001287A1 (es)	2018-03-16	Benzamidas sustituidas y procedimiento para su uso
UY37133A (es)	2017-09-29	Derivados de pirazolo[1,5-a]pirazin-4-ilo
MX2016012984A (es)	2017-05-09	Derivados indol para uso en medicina.
AR100418A1 (es)	2016-10-05	Compuestos y composiciones para inducir condrogénesis
EA201791692A1 (ru)	2018-01-31	4H-ПИРРОЛО[3,2-c]ПИРИДИН-4-ОНОВЫЕ ПРОИЗВОДНЫЕ
AR089285A1 (es)	2014-08-13	Derivados de betulina
AR099228A1 (es)	2016-07-06	Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos
AR104878A1 (es)	2017-08-23	MODULADORES DE ROR GAMMA (RORg)
AR094550A1 (es)	2015-08-12	Inhibidores de btk
AR093036A1 (es)	2015-05-13	Derivados de pirrolotriazinona como inhibidores de pi3k
TW201613603A (en)	2016-04-16	Pharmaceutical preparation
AR090572A1 (es)	2014-11-19	Derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos
AR100808A1 (es)	2016-11-02	Inhibidores de fosfatidilinositol 3-quinasa
AR102258A1 (es)	2017-02-15	Compuestos de quinolina y quinazolina
MX2016012451A (es)	2017-01-06	Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina.
AR091781A1 (es)	2015-02-25	Antagonistas del receptor de 5-ht3
MX2018013164A (es)	2019-06-24	Compuestos novedosos de imidazopiridina sustituida como inhibidores de indolamina-2,3-dioxigenasa y/o triptofano-2,3-dioxigenasa.
AR112907A1 (es)	2020-01-08	Pirazoles inhibidores de monoacilglicerol lipasa (magl)